What is HC Wainwright’s Estimate for Cybin FY2029 Earnings?

Cybin Inc. (NYSE:CYBN) – Analysts at HC Wainwright dropped their FY2029 earnings per share (EPS) estimates for Cybin in a research note issued to investors on Monday, January 27th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of $8.87 for the year, down from their prior estimate of $9.57. HC Wainwright currently has a “Buy” rating and a $190.00 target price on the stock. The consensus estimate for Cybin’s current full-year earnings is ($4.88) per share.

Separately, Canaccord Genuity Group decreased their price objective on Cybin from $96.00 to $86.00 and set a “buy” rating for the company in a research note on Thursday, November 14th.

Cybin Stock Performance

Shares of CYBN stock opened at $9.86 on Wednesday. The stock has a 50-day moving average price of $9.78. The firm has a market capitalization of $197.83 million, a price-to-earnings ratio of -1.48 and a beta of 0.44. Cybin has a 12 month low of $6.50 and a 12 month high of $19.85.

Hedge Funds Weigh In On Cybin

An institutional investor recently bought a new position in Cybin stock. Sanctuary Advisors LLC acquired a new stake in Cybin Inc. (NYSE:CYBN) in the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 131,252 shares of the company’s stock, valued at approximately $36,000. Hedge funds and other institutional investors own 17.94% of the company’s stock.

About Cybin

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.